Renaissance Capital logo

IPO News & Commentary

Get the latest insights on new stocks

Phase 1 solid tumor biotech Aktis Oncology prices IPO at $18, the high end of the range

Aktis Oncology logo

Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, raised $318 million by offering 17.7 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer 11.8 million shares at ...read more

SPAC Cantor Equity Partners VI files for a $100 million IPO

Cantor Equity Partners VI, the fifteenth blank check company formed by Cantor Fitzgerald, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. The company plans to raise $100 million by offering 10 million shares at $10....read more

SPAC Bleichroeder Acquisition II prices $250 million IPO, targeting technology

Bleichroeder Acquisition II, a blank check company led by investment veterans targeting technology, raised $250 million by offering 25 million units at $10.00. Each unit consists of one share of common stock and one-third of one warrant, exercisable at $11.50. ...read more

IPO News By Industry

Be the in-house IPO Expert

Our clients are focused on catalyzing growth and creating value.

Not scouring the web for IPO data.

Get the information you need in minutes, not hours. With IPO Pro, you have the entire US IPO market at your fingertips.